United Kingdom · Question · Written question
UIN 21879
Myelodysplastic Syndromes: Drugs
Introduced
24 June 2021
Last action
29 June 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
29 June 2021
Summary
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure equitable access to Exjade for Myelodysplastic Syndrome patients across the country.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
24 June 2021
Written question
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure equitable access to Exjade for Myelodysplastic Syndrome patients across the country.
Source: Commons
29 June 2021
Answer
Exjade (Deferasirox) is not licensed by the Medicines and Healthcare products Regulatory Agency to treat Myelodysplastic Syndrome. Clinicians are able to prescribe any product on the National Health Service they consider necessary for the treatment of the...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-06-24/21879
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1339969
- uk · wq-1339969 · source updated 29 June 2021